MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

MDSpire News

  • September 14, 2026
FDA broadens APDS treatment options
  • Kathryn Wighton
  • September 14, 2026
  • 3 min
  1. The FDA has approved leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in pediatric patients aged 4 to 11 years.
  2. Leniolisib was initially approved for patients aged 12 years and older in 2023, targeting a rare genetic disorder affecting the immune system.
  3. APDS can cause recurrent infections and enlargement of lymph nodes, tonsils, and spleen, potentially leading to airway and gastrointestinal obstruction.
  4. Efficacy for older patients was demonstrated in a 12-week study showing reduced lymph node size and improved naïve B-cell counts with leniolisib.
  5. Common adverse effects in younger patients include abdominal pain, respiratory infections, diarrhea, and headache; leniolisib is contraindicated in severe liver impairment.
...more

MDSpire News

  • September 14, 2026
FDA approves muscle-targeted SMA therapy
  • Kathryn Wighton
  • September 14, 2026
  • 2 min
  1. The FDA approved apitegromab-mstn (Isembyld) for spinal muscular atrophy in patients aged 2 years and older.
  2. Apitegromab is a monoclonal antibody designed to inhibit myostatin signaling in spinal muscular atrophy.
  3. The approval was based on the SAPPHIRE trial, which included 188 patients aged 2 to 21 years with 5q SMA.
  4. Patients receiving apitegromab 10 mg/kg showed a 2.2-point improvement on the Hammersmith scale compared to placebo.
  5. Common adverse reactions included upper respiratory infections, vomiting, and fractures in 9% of patients on apitegromab.
...more

MDSpire News

  • September 14, 2026
FDA approves FET-PET agent for glioma
  • Kathryn Wighton
  • September 14, 2026
  • 2 min

Objective: To inform about the FDA approval of floretyrosine F 18 (Pixclara) for PET imaging in glioma. Approach: FDA Approval: The FDA approved floretyrosine F

...more
1 min

Baptist Health South Florida

  • September 14, 2026
CREST-2 Findings Highlight Evolving Role of Carotid Artery Stenting
  • September 14, 2026
  • 5 min

Objective: To assess the role of carotid artery stenting (CAS) in patients with severe asymptomatic carotid stenosis and its effectiveness alongside intensive m

...more

MDSpire News

  • September 14, 2026
Medical Oddities: When orgasm sets off the immune system
  • Teraya Smith
  • September 14, 2026
  • 6 min
  1. Post-orgasmic illness syndrome (POIS) causes fatigue, flu-like symptoms, and neuropsychiatric changes after orgasm.
  2. A narrative review suggests POIS may involve a multisystem inflammatory response rather than simple histamine intolerance.
  3. 88% of men with POIS in a study had a positive skin response to their own semen, but this does not explain all cases.
  4. Treatment options for POIS include antihistamines, corticosteroids, and omalizumab, which has shown promising results.
  5. Further controlled studies are needed to understand POIS biology and treatment responses.
...more

The Pathologist

  • September 14, 2026
ECP 2026: Is HPV-Specific Testing Optimized in Throat Cancer?
  • September 14, 2026
  • 2 min

Objective: To investigate the current practice of HPV-specific testing in oropharyngeal squamous cell carcinoma among head and neck pathologists in the UK and I

...more

The Pathologist

  • September 14, 2026
Measles Returns as Vaccination Rates Fall
  • Jessica Allerton
  • September 14, 2026
  • 3 min

Objective: To discuss the resurgence of measles in the U.S. linked to declining vaccination rates. Approach: Vaccination Coverage: The increase in measles cases

...more

The Analytical Scientist

  • September 14, 2026
A Finer Approach to Native MS
  • September 14, 2026
  • 11 min
  1. Native mass spectrometry (MS) faces limitations due to sample compatibility with volatile buffers affecting protein stability.
  2. Nanopipette emitters can adapt the ionization process in native MS, allowing analysis of proteins in biochemical buffers.
  3. Smaller droplet sizes from nanopipettes reduce salt adduction and improve desolvation, enhancing the quality of mass spectra.
  4. The study demonstrated that nanopipette emitters are transferable across different MS platforms and protein types.
  5. This approach reduces sample preparation workload and mitigates issues like sample loss and aggregation in native MS.
...more

Frontiers In Medicine

  • September 14, 2026
Impact of Prolonged Inhaled Corticosteroid Use on Growth Rate and Final Height in Pediatric Asthma: A Systematic Review and Meta-Analysis
  • Jinguang Zhao
  • Aiai Dong
  • Yibu Kong
  • Tianlong Xie
  • Xinyan Yu
  • Baoxin Li
  • Tianbao Tan
  • Jiqiang Mi
  • Yinan Guo
  • September 14, 2026
  1. This systematic review and meta-analysis evaluated the impact of prolonged inhaled corticosteroid use on growth in children with asthma.
  2. Thirteen studies met the inclusion criteria, with six providing data for quantitative analysis on linear growth velocity.
  3. The primary analysis showed no significant reduction in linear growth velocity with ICS treatment, but sensitivity analysis indicated a potential small decrease.
  4. Among school-age children, a reduction in growth velocity was observed, while evidence on adult height was limited and suggested a small decrease.
  5. The findings warrant cautious interpretation, considering the established benefits of inhaled corticosteroids in asthma management.
...more

Frontiers In Medicine

  • September 14, 2026
Management of Non-Sjögren's Dry Eye (Shushkakshipaka) in Preparation for Cataract Surgery: A Case Study
  • Sushma Naranappa Salethoor
  • Anil Radhakrishnan
  • Shyamasundaran Kulangara
  • Ramya Shruthi Janardhanan
  • Rammanohar Puthiyedath
  • Reshma NS
  • September 14, 2026

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Frontiers In Medicine

  • September 14, 2026
Link Between Neutrophil Percentage-to-Albumin Ratio and 90-Day Mortality in Patients with Acute-on-Chronic Liver Failure
  • Jiahua Hu
  • Lu Li
  • Xiaoli Yang
  • Maohua Guo
  • September 14, 2026
  1. The study examined the relationship between the neutrophil percentage-to-albumin ratio (NPAR) and 90-day mortality in patients with acute-on-chronic liver failure (ACLF).
  2. Among 104 patients, 29 (27.9%) died within 90 days, with NPAR significantly higher in the non-survivor group compared to survivors (P < 0.001).
  3. Log-transformed NPAR was associated with mortality in univariate analysis, showing an odds ratio of 2.67 for each 1-unit increase (P = 0.041).
  4. After adjusting for the MELD score, the association between NPAR and 90-day mortality was no longer statistically significant (adjusted OR: 1.66, P = 0.484).
  5. The study suggests that larger studies are needed to evaluate whether NPAR provides prognostic information beyond established severity scores.
...more

Frontiers In Cardiovascular Medicine

  • September 14, 2026
Correction: Precision Cardiac Rehabilitation Utilizing Dynamic Navigation and Blood Metabolomics: Advancing Risk Stratification and Real-Time Intervention Enhancement
  • Hejuan Hua
  • Yanbing Chen
  • Tianyi Yu
  • September 14, 2026
  1. The article corrects the affiliation of Hejuan Hua to the Department of Cardiology at First People's Hospital of Xiaoshan District.
  2. The previously incorrect association of Hejuan Hua with the Department of Rehabilitation has been removed.
  3. The correction addresses both missing and erroneous affiliations in the original article.
  4. The updated article is published in Front Cardiovasc Med, volume 13, article 1805494.
  5. The DOI for the corrected article is 10.3389/fcvm.2026.1805494.
...more

Npj Digital Medicine

  • September 14, 2026
Collaborative Multi-Agent Framework as an Enhancing Structure for AI-Generated Medical Assessment Questions
  • Zhehan Jiang
  • September 14, 2026

Objective: To propose a multi-agent framework that enhances the quality of AI-generated medical assessment questions by mimicking established collaborative item

...more
3 min

Frontiers In Oncology

  • September 14, 2026
Evaluation of Computationally Identified Small Molecules Targeting the YAP–TEAD Interaction in Mesothelioma Cell Models with Altered Hippo Pathway Activity
  • Glen J. Weiss
  • Joseph C. Loftus
  • David W. Mallery
  • Nhan L. Tran
  • September 14, 2026
  1. The study evaluated small molecules targeting the YAP–TEAD interaction in mesothelioma cell models with altered Hippo pathway activity.
  2. Computational screening of approximately 917,000 compounds identified candidates for experimental assessment of their antiproliferative effects.
  3. The validated TEAD inhibitor K-975 showed dose-dependent antiproliferative effects in some mesothelioma cell lines, while cisplatin decreased viability in all.
  4. None of the computationally nominated compounds demonstrated measurable antiproliferative activity at the tested concentrations.
  5. The findings highlight a limited concordance between computational nominations and actual cell-based activity in targeting the YAP–TEAD interface.
...more

Frontiers In Oncology

  • September 14, 2026
Analysis of Liquid Biopsy Utilizing ctDNA and cfDNA in Bladder Cancer and Urothelial Carcinoma: A Bibliometric Review and Database Coverage Assessment from 2008 to 2025
  • Junhua Li
  • Chenhao Tang
  • Longfei Yang
  • Chen Song
  • Huixian Pan
  • September 14, 2026
  1. The study analyzes the growth and coverage of literature on ctDNA and cfDNA in bladder cancer from 2008 to 2025.
  2. A total of 1,903 records were found in WoSCC, 3,201 in Scopus, and 230 in PubMed/MEDLINE, indicating varied database coverage.
  3. The main set of 494 records accumulated 17,031 citations, with a peak annual output of 82 records in 2025.
  4. The research highlights a shift from early methylation studies to ctDNA-based evaluations for molecular residual disease.
  5. Bibliometric prominence reflects research activity rather than diagnostic accuracy or treatment benefit in bladder cancer.
...more

Frontiers In Oncology

  • September 14, 2026
Assessment of PD-L1 Expression, Mismatch Repair Status, and Survival Rates in Colorectal Cancer: A Retrospective Study from Pakistan
  • Kanza Atif
  • Aiman Ajmeer
  • Abdal Ahmad
  • Fozia Rauf
  • Umer Khan
  • Sarah Yousuf
  • Bilal Ahmad
  • Sadia Qazi
  • September 14, 2026
  1. The study evaluated PD-L1 expression in colorectal cancer using the ZR3 clone in a cohort of 60 patients from Pakistan.
  2. PD-L1 expression was detected in 71.7% of tumors, with 31 low-positive and 12 high-positive cases, reflecting assay-specific behavior.
  3. MSI-H/dMMR status was found in 20% of tumors and correlated with high PD-L1 expression, but no association was observed with binary PD-L1 positivity.
  4. PD-L1 status showed no relationship with overall survival, disease-free survival, or progression-free survival in the studied cohort.
  5. The study concluded that PD-L1 TPS should remain a research measure, while MSI/MMR testing is the clinically actionable biomarker for CRC.
...more

Frontiers In Medicine

  • September 14, 2026
Management of Concurrent Alopecia Areata and Systemic Lupus Erythematosus Using Ivarmacitinib: A Case Study and Review of Existing Literature
  • Wenjie Li
  • Zisheng Zhang
  • Ruoxin Huang
  • Yanni Mei
  • Zhengdong Shen
  • Yongliang Chu
  • September 14, 2026
  1. A 35-year-old woman with severe patchy hair loss was diagnosed with systemic lupus erythematosus after ineffective treatment for alopecia areata.
  2. Ivarmacitinib, a selective JAK 1 inhibitor, led to marked clinical improvement in the patient's alopecia after previous treatments failed.
  3. Trichoscopy findings after treatment included features consistent with both alopecia areata and lupus-associated alopecia.
  4. The patient achieved an 80% reduction in the Severity of Alopecia Tool (SALT) score after 10 months of ivarmacitinib treatment.
  5. This case highlights the diagnostic challenges of overlapping alopecic disorders and the potential role of JAK inhibitors in treatment.
...more

Frontiers In Medicine

  • September 14, 2026
Meta-Analysis of Deep Learning Approaches for Detecting Pancreatic Cancer via CT Imaging
  • Yunxia Ding
  • Han Qin
  • Zhen Qu
  • Jiangyi Ju
  • Lihua Peng
  • September 14, 2026
  1. This meta-analysis evaluated the diagnostic accuracy of deep learning models for detecting pancreatic ductal adenocarcinoma using CT scans.
  2. Fifteen studies met the inclusion criteria, showing a pooled sensitivity of 0.92 and specificity of 0.96 for deep learning models.
  3. The pooled diagnostic odds ratio was 285.00, and the area under the curve was 0.97, indicating high diagnostic accuracy.
  4. Subgroup analysis revealed a pooled sensitivity of 0.73 and specificity of 0.92 for scans obtained 3 to 36 months before clinical diagnosis.
  5. All studies were retrospective, and the authors emphasized the need for prospective validation before clinical integration of these models.
...more